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Abstract
 .  .  .Glucagon-like-peptide-1 7–36 amide GLP-1 , when infused into the third ventricle IVT , reduces short-term food intake. In the
present experiments, we assessed whether IVT administration of GLP-1 could influence long-term food intake and body weight of lean
 .Long Evans rats and of fatty Zucker farfa rats. In Experiment 1, we replicated the observation that 10 mg GLP-1, given IVT, reduces
one and 2 h food intake, and extended the observation to fatty Zucker rats. However, in both rat strains, 24 h food intake and body weight
 .were unchanged by this acute treatment. In Experiment 2, GLP-1 30 mgrday was infused IVT continuously for 4 days via an osmotic
mini-pump. This treatment also had no effect on food intake or body weight in either Long–Evans or fatty Zucker rats. A control
experiment verified that the GLP-1 remained biologically active over the duration of the infusion period. In a final experiment,
Long-Evans rats were restricted to two 2 h periods of access to food each day for 6 days. Prior to each of these access periods, rats
received either 15 mg of GLP-1 IVT or a vehicle control injection. While GLP-1 significantly reduced food intake on the first day of
treatment, this effect of GLP-1 rapidly disappeared such that it was reduced on the second day and absent on the third day; and there was
no effect on body weight at any time. Collectively, the present experiments do not support the hypothesis that GLP-1, acting in the CNS,
is an important regulator of long-term food intake and body weight. q 1998 Elsevier Science B.V.
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1. Introduction
The accurate regulation of food intake and body weight
depends on the complex interaction of several regulatory
systems. Some of these systems appear to act primarily at
the level of individual bouts of ingestion or meals. The
prototypical compound for such a short-term satiety signal
 .is the gut peptide cholecystokinin CCK which is secreted
in response to food in the upper intestine. When adminis-
tered intraperitoneally or directly into the central nervous
 .system CNS , CCK causes a potent reduction in the size
w xof the subsequent meal 16 . After such treatment, how-
ever, total daily food intake is not different from that of
w xcontrols 22 . This implies that the effect of CCK is
short-lived, and that animals eat more in subsequent meals
in order to compensate for the lost calories from the
reduced first meal in order to maintain daily caloric intake
)  .Corresponding author. Fax: q1 513 558-8990; E-mail:
seeleyr@uc.campus.mci.net
w xand body weight constant 22 . When CCK is administered
at the onset of each spontaneous meal in non-deprived and
freely feeding rats, it reliably reduces the size of each meal
compared to the meal size of control animals, but daily
caloric intake and body weight are unchanged because
animals receiving CCK compensate by increasing the num-
w xber of individual meals they take 22 . Hence, satiety
factors such as CCK, if given alone, are unlikely to
provide effective therapeutic tools for obesity.
A second category of peptides, including insulin and
leptin, act in a fundamentally different manner. When
administered continuously into the CNS over days, insulin
or leptin produces persistent reductions in daily caloric
intake and body weight at doses that have no effect when
w xadministered into the periphery 15,23 suggesting that the
CNS is the likely target for this action. Since both insulin
and leptin are secreted in proportion to body adiposity,
each has been considered a likely factor that interacts with
meal-generated satiety factors in the long-term control of
w xbody adiposity 13,24 . Consistent with this, there is evi-
0006-8993r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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dence that the administration of small amounts of insulin
 .and possibly leptin potentiates the action of meal-gener-
w xated satiety factors such as CCK 14 . Hence, when an
animal loses weight, it secretes less insulin and leptin, and
satiety factors such as CCK are rendered less effective.
One result is larger meals until weight is restored. The
opposite occurs if an animal gains weight. In this way
adiposity factors act in concert with satiety factors to
coordinate food intake with the maintenance of total body
adiposity.
Turton and colleagues have proposed that glucagon-
 .  .like-peptide-1 7–36 amide GLP-1 , acting at receptors
in the CNS, is an endogenous factor important in the
w xregulation of food intake 17,19 . GLP-1 is secreted from
the distal gut in response to the presence of mixed nutri-
w xents in the gastrointestinal tract 3,8 . In the periphery,
GLP-1 influences glucose homeostasis after ingestion of
carbohydrate meals via modulation of gastric emptying
and alteration of the secretion of insulin and glucagon
w x from the pancreas 2 . The precursor for GLP-1 prepro-
.glucagon is also synthesized in the CNS in the nucleus of
 . w xthe solitary tract NTS 4,7,10 . Receptors for GLP-1 are
concentrated in the paraventricular nucleus of the hypo-
 .thalamus PVN , the amygdala, and several regions of the
w xbrainstem including the area postrema and the NTS 5 . In
w xtheir report, Turton et al. 19 observed that bolus adminis-
tration of GLP-1 into the third ventricle of lean rats
produced a potent and dose-dependent reduction of 2 h
food intake, and they further reported that this reduction
could be blocked by pretreatment with the specific GLP-1
receptor antagonist, exendin. Based on these findings, they
proposed GLP-1 as a natural regulator of food intake and
possibly adiposity as well. The purpose of the present
experiments was to determine whether central administra-
tion of GLP-1 alters long-term food intake and body
weight in lean Long–Evans rats and in genetically obese
 .farfa Zucker rats. We therefore sought to determine
whether GLP-1 acts in the CNS as a short-term regulator
of food intake, as occurs with CCK, or as a long-term
adiposity-type signal such as leptin or insulin.
2. Materials and methods
2.1. Animals
Male Long–Evans rats were obtained from the vivarium
maintained by the Department of Psychology at the Uni-
 .versity of Washington; and female fatty Zucker rats farfa
were obtained from Harlan Inc. Rats were individually
 .housed in stainless steel hanging cages Long Evans or
 .plexiglass tubs with shavings on the floor Zuckers . The
rooms were maintained on 12:12 h light:dark cycle in a
temperature-controlled room. Except where noted, animals
were maintained on ad lib water and pelleted chow.
2.2. Surgical preparation
 . Under ketamine 9 mgrkg; i.p. and xylazine 1.5
.mgrkg; i.p. anesthesia, rats were implanted with 21-gauge
 .stainless steel cannulae Plastics One, Roanoke, VA aimed
w xat the third cerebral ventricle as described previously 1 .
Stereotaxic techniques were used to implant a guide sleeve
directly on the midline, 2.2 mm posterior to bregma, with
its tip 7.5 mm ventral to dura. The cannula was secured to
the skull with screws and dental acrylic, and following
implantation was fitted with a removable obturator which
extended 0.5 mm beyond the tip of the guide sleeve.
Following surgery, all animals were prophyllactically in-
jected with 0.15 ml of both Chloromycetin 100 mgrml;
.  .s.c. and Gentamiacin 40 mgrml; i.m. , and then were
allowed at least one week to recover before an experiment
began. Rats were also injected with Chloromycetin 100
.mgrml; s.c. on any day that infusions were made into the
cannulae. Cannula patency was confirmed by administra-
 .tion of angiotensin-II 10 ng in 1 ml saline . Animals
which failed to consume 5 ml water in 60 min following
injection were not included.
2.3. Drugs
 .Glucagon-like-peptide-1 7–36 amide was purchased
from American Peptide Co., Sunnyvale, CA. Sterile saline
served as vehicle for GLP-1 injections.
2.3.1. Experiment 1
 .2.3.1.1. Animals. Twelve Long–Evans 306 to 368 g and
 .16 fatty Zucker rats 403 to 546 g were maintained and
surgically prepared as described above.
2.3.1.2. Procedure. Two hours before lights out, food
hoppers were removed and weighed. One hour later, each
rat was removed from its cage and weighed, the obturator
was removed and a 26-gauge infusion cannula extending
1.0 mm beyond the tip of the guide cannula was inserted.
The infusion cannula was connected to a Hamilton syringe
 .via PE-50 tubing, and solutions 3 ml were infused manu-
 .ally over 60 s. Half of the rats received GLP-1 10 mg ,
and the other half received sterile saline. At lights out, the
food hoppers were replaced on the cages and intake was
 .determined after 1, 2 and 24 h Long Evans and after 2
 .and 24 h fatty Zuckers . Rats were weighed 24 h after the
injections.
2.3.2. Experiment 2
 .2.3.2.1. Animals. Eleven Long–Evans 280 to 388 g and
 .13 fatty Zucker rats 432 to 614 g that had been used in
Experiment 1 served as subjects in Experiment 2. For this
experiment, no chow was available and rats were placed
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on a regimen in which they had access to the nutritionally
 .complete liquid diet, Ensure Ross Labs , for 17 h daily
starting 2 h before lights out. Animals were adapted to this
schedule prior to the start of the experiment.
2.3.2.2. Procedure. On Day 1, rats were briefly anes-
thetized with ketaminerxylazine and implanted subcuta-
 .neously with an osmotic minipump Alzet, 2002 that
infused at a rate of 0.5 mlrh. The minipump was filled
with sterile saline and was connected to tubing which
contained )60 ml of either GLP-1 30 mgr12 mlrday;
.ns6 Long–Evans and ns6 fatty Zuckers or sterile
saline 12 mlrday; ns5 Long–Evans and ns7 fatty
.Zuckers . An air bubble separated the solution in the pump
from that in the tubing. The other end of the tubing was
connected to a 26-gauge infusion cannula, which was
inserted into the guide sleeve and extended 1.0 mm beyond
its tip. Over four days following implantation, intake of
Ensure, and body weight, were measured daily. At the end
of the fourth day, animals were sacrificed and both the
presence of the bubble and its movement along the tubing
were verified to ensure that experimental solutions re-
mained separate and had infused properly.
2.3.3. Experiment 3
2.3.3.1. Animals. Twelve Long–Evans rats weighing from
409 to 555 g with third ventricle cannulas were used for
Experiment 3. These animals had been used in a previous,
unrelated experiment.
 .2.3.3.2. Procedure. GLP-1 150 mgr60 ml saline and
saline were placed in the same tubing used for mini-pump
infusions, sealed and left in a temperature controlled water
bath at 388C for 4 days. Then the solutions were removed
from tubing and half the animals received an ICV injection
 .  .of GLP-1 10 mgr3 ml or saline 3 ml and food intake
was measured as in Experiment 1.
2.3.4. Experiment 4
 .2.3.4.1. Animals. Fourteen Long–Evans rats 292 to 350 g
were surgically prepared as described above. Following
recovery from surgery, rats were adapted to a meal-feeding
schedule on which they had access to pelleted chow during
two 2 h periods per day. Meal 1 began 2 h after lights on,
and meal 2 began 8 h after lights on. The subjects were
able to maintain their ad lib fed body weights on this
schedule.
2.3.4.2. Procedure. On five consecutive days, rats received
 .bolus IVT injections of either GLP-1 15 mgr3 ml; ns6
 .or sterile saline 3 ml; ns8 1 h before each meal. Food
hoppers were weighed before and after each meal, and
body weights were recorded before the first meal each day.
On Day 6, rats were maintained on the same feeding
schedule, but did not receive any injections.
3. Results
3.1. Experiment 1
The purpose of this experiment was to determine if
 .single intraventricular ivt injections of GLP-1 reduce
food intake of Long Evans and of fatty Zucker rats. Data
were analyzed with the Student’s t-test, with p-0.05
 .two-tailed indicating significance.
In the first hour following injection, Long Evans rats
receiving GLP-1 consumed significantly less chow than
 .saline controls 0.7 vs. 2.6 g, p-0.001; Fig. 1, top panel .
After 2 and 24 h, intake of the two groups did not differ
reliably 2 h:2.1 vs. 3.6 g, ps0.074; 24 h:11.1 vs. 13.2 g,
.ps0.71 . Change in body weight over the 24 h following
injection also did not differ reliably between groups ps
.0.75 .
In the first 2 h following injection, fatty Zucker rats
receiving GLP-1 consumed significantly less chow than
their saline controls 1.6 vs. 4.1 g, p-0.001; Fig. 1,
.bottom panel . After 24 h, the difference was no longer
 .reliable 12.7 vs. 12.6 g, ps0.98 . Change in body
weight over the 24 h following injection also did not differ
 .reliably between the two groups of fatty rats ps0.54 .
Whereas GLP-1 initially and robustly reduced food
 .intake in both strains of rat i.e., over the first 1 to 2 h ,
this reduction was completely compensated by the end of
the 24 h period. These findings therefore replicate and
w xextend the observations of Turton et al. 19 . Consistent
with that report, GLP-1 is highly efficacious in the short
term, but the effects of a single injection are short-lived.
One new observation is that obese Zucker rats are compa-
rably sensitive to this anorexic effect of GLP-1.
3.2. Experiment 2
The purpose of this experiment was to determine
whether chronic administration of GLP-1, lasting several
days, would reduce food intake and body weight. Results
were analyzed by a repeated measures ANOVA followed
 .by additional ANOVAs. Condition saline vs. GLP-1
served as the between-groups variable, while Day of mea-
surement served as the within-group variable.
Daily food intake of Long–Evans rats receiving either
chronic infusions of saline or GLP-1 is depicted in Fig. 2,
 w xtop panel. ANOVA revealed no effect of Condition F 1,8
.s0.18, ps0.68 on food intake, but a significant effect
 w x .of Day F 4,32 s18.91, p-0.001 and a significant
 w xinteraction between Condition and Day F 4,32 s3.05,
.p-0.05 . Follow-up ANOVA comparison of baseline in-
take vs. intake on Days 1 through 4 revealed a significant
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 .  .  .Fig. 1. The effect of a bolus ICV injection of GLP-1 10 mg on chow intake in Long–Evans top panel and farfa Zucker rats bottom panel . Data are
represented as mean"S.E.M. and ) indicates statistically different from vehicle at p-0.05.
 w xeffect of Day on Days 1 and 2 F 1,9 s98.99, p-0.001,
w x .and F 1.8 s12.50, p-0.01, respectively , but no inter-
actions of Condition and Day.
Body weights of Long–Evans receiving infusions of
saline or GLP-1 are depicted in Fig. 2, bottom panel.
ANOVA revealed no significant effects of either Condition
 w x .  w xF 1,9 s1.92, ps0.199 , Day F 4,36 s0.28, ps
.  w x0.891 , or the interaction between the variables F 4,36 s
.1.12, ps0.363 .
Food intake of fatty Zucker rats receiving infusions of
saline or GLP-1 is depicted in Fig. 3, top panel. ANOVA
 w xrevealed no significant effect of Condition F 1,11 s0.04,
.  w xps0.853 . The effect of Day was significant F 4,44 s
.45.67, p-0.001 , and the interaction was not significant
 w x .F 4,44 s0.84, ps0.51 . Follow-up ANOVA compar-
ing pre-surgical intake with Days 1 through 4 revealed a
 w xsignificant effect of Day for each comparison F 1,11 s
w x w x150.11, p-0.001; F 1,11 s43.48, p-0.001; F 1,11
ws28.24, p-0.001; and F 1,11s34.07, p-0.001, for
.Days 1 through 4, respectively , but no effect of Condition
and no significant interactions.
Body weights of fatty Zucker rats are depicted in Fig. 3
bottom panel. ANOVA revealed no overall effect of Con-
 w x .dition F 1,10 s0.04, ps0.849 . Similar to the observa-
tions with food intake, there was a significant overall
 w xeffect of Day on body weight F 4,40 s14.62, p-
.0.001 , but no interaction between Condition and Day
 w x .F 4,40 s0.21, p-0.93 . Follow-up ANOVA compar-
ing pre-surgical body weight with weight on experimental
days 1 through 4 revealed a significant effect of Day for
 w x w xeach comparison F 1,11 s44.43, p-0.001; F 1,10 s
w x w x23.01, p-0.01; F 1,11 s24.95, p-0.001; and F 1,11
.s13.32, p-0.01, for Days 1 through 4, respectively .
There were no significant effects of Condition and no
significant interactions for any of the comparisons of
individual days to pre-surgical weight.
In this experiment, GLP-1 infusion failed to effect food
intake or body weight over a several-day interval relative
to a saline infusion. The treatment paradigm per se resulted
in a non-specific reduction of food intake from baseline
likely do to the stress of anesthesia and surgical manipula-
.tion at the time of mini-pump placement over the course
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of the infusion in both Long Evans and fatty Zucker rats,
but the magnitude of the effect was comparable for saline
and GLP-1 treatments. The non-specific reduction of food
intake was insufficient to reduce the body weight in the
Long Evans rats but did do so, albeit slightly in the fatty
Zucker rats. Such non-specific reductions in food intake do
present an interpretive difficulty. It is possible that this
reduction masked an effect of GLP-1 to reduce food intake
over the long term. It is important to note, however, that
the lack of a drug effect on body weight in both groups fail
to provide evidence that GLP-1 can cause long-term reduc-
tions in body weight in this paradigm.
3.3. Experiment 3
The lack of effect of GLP-1 in Experiment 2 could have
resulted from the method of administration. It is possible,
for example, that when kept in solution in a small-diameter
tube at body temperature for several days, GLP-1 loses its
potency. The purpose of this experiment was to assess this
possibility. Data were analyzed using a Student’s t-test.
GLP-1 produced a significant reduction in food intake
 .at 1 and 2 h p-0.001, see Fig. 4 but not after 24 h after
the exposure to the tubing and body temperatures for 4
days that was comparable to Experiment 2 using the
osmotic mini-pump. The results of this experiment suggest
that the GLP-1 in Experiment 2 had maintained its potency
throughout the time of the infusion. Hence, the lack of
effect of GLP-1 on food intake or body weight cannot be
attributed to a loss of biological activity of the GLP-1 per
se.
3.4. Experiment 4
Another possible interpretation of the lack of effect of
GLP-1 in Experiment 2 is that the chronic pattern of
 .  .  .Fig. 2. The effect of continuous 4-day ICV infusion of GLP-1 30 mgrday on ensure intake top panel and body weight bottom panel in Long–Evans
rats. Data are represented as mean"S.E.M.
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 .  .  .Fig. 3. The effect of continuous 4-day ICV infusion of GLP-1 30 mgrday on ensure intake top panel and body weight bottom panel in Long–Evans
rats. Data are represented as mean"S.E.M.
administration failed to mimic a physiological pattern of
secretion. In the present experiment, we therefore adminis-
tered the same daily dose of GLP-1 that was used in
Experiment 2, but as a bolus just prior to each bout of
feeding. These bouts of feeding were 2 h in duration, a
duration over which we and others have reported reduced
feeding for GLP-1. Results were analyzed by a repeated
 .measures ANOVA. Condition saline vs. GLP-1 served as
the between-groups variable, while Day of measurement
served as the within-group variable.
The effect of repeated bolus injections of saline or
GLP-1 on food intake are depicted in Fig. 5A. ANOVA
 w xrevealed no significant overall effect of Condition F 1,12
.s2.48, ps0.141 . There was a significant effect of Day
 w x .F 6,72 s10.23, p-0.001 and a significant interaction
 w x .between Condition and Day F 6,72 s4.04, p-0.01 .
 .Fig. 4. The effect of a bolus ICV injection of GLP-1 10 mg on chow
intake in Long–Evans rats after that GLP-1 had been held in osmotic
mini-pump tubing and kept at body temperature for 4 days. Data are
represented as mean"S.E.M. and ) indicates statistically different from
vehicle at p-0.05.
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 .Fig. 5. The effect of two daily bolus ICV injections of GLP-1 30 mgrday on chow intake in Long–Evans rats that were constrained to two 2 h periods of
 .  . )access to food per day on total daily food intake top panel and body weight bottom panel . Data are represented as mean"S.E.M. and indicates
statistically different from vehicle at p-0.05.
To analyze this interaction, follow-up ANOVA’s were
performed. Comparing baseline intake with Day 1 of treat-
 w xment revealed a significant effect of Condition F 1,12 s
.  w x .13.56, p-0.01 , Day F 1,12 s30.09, p-0.001 and
 w xthe interaction between Condition and Day F 1,12 s
.22.61, p-0.001 . By Day 2, the comparison with base-
 w xline intake revealed no effect of Condition F 1,12 s1.82,
.  w x .ps0.202 , and no interaction F 1,12 s1.82, ps0.202 ,
 w xbut a significant effect of Day F 1,12 s30.09, p-
.0.001 .
The effect of repeated bolus injections of saline or
GLP-1 on body weight is depicted in Fig. 5B. ANOVA
revealed a significant overall effect of Day on body weight
 w x .F 7, 84 s26.16, p-0.001 , but no effect of Condition
 w x .  w xF 1,12 s0.88, ps0.367 and no interaction F 7,84 s
.0.83, ps0.566 . In comparison to baseline body weight,
on Days 1 through 6, all rats’ body weights were signifi-
 w xcantly reduced, regardless of condition F 1,12 s7.32,
w x w xp-0.05; F 1,12 s38.32, p-0.001; F 1,12 s237.84,
w x w xp - 0.001; F 1,12 s 121.63, p - 0.001; F 1,12 s
w x121.88, p-0.001; and F 1,12 s95.42, p-0.001, for
.Days 1 through 6, respectively . By day 7, all rats had
 w xreturned to their pre-treatment weight F 1,12 s3.32,
.ps0.93 . Over the course of the six days of the experi-
ment, change in body weight did not differ as a function of
GLP-1 treatment. In fact, even when food intake was
suppressed by GLP-1, body weight was not reduced rela-
tive to that of the saline controls.
These results replicate and extend the results of Experi-
ment 1. On the first day of treatment the bolus injections
of GLP-1 suppressed food intake when the animals only
were allowed short-term feeding bouts of 2 h each. How-
ever, from Day 2 until the end of the experiment, food
intake of rats receiving GLP-1 was no longer suppressed
relative to that of saline-injected controls. Therefore, the
rats receiving GLP-1 quickly compensated for the initial
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reduction in food intake. The fact that food intake was
initially reduced indicates that the GLP-1 was effective. As
in experiment 2, food access restriction combined with
multiple third ventricle injections produced a non-specific
reduction in food intake and a small reduction in body
weight. The possibility that these non-specific effects of
the control condition masked a small effect of GLP-1 can
not be eliminated. As in the previous experiments, how-
ever, the inability of GLP-1 to produce an effect over and
above the appropriate control conditions do not support a
role for GLP-1 in the regulation of long-term food intake
and body weight.
4. General discussion
w xThe current results replicate those of Turton et al. 19
demonstrating that when administered into the third ventri-
cle, GLP-1 potently reduces food intake, and that the effect
lasts for up to 2 h in lean Long–Evans rats. The current
experiments extend the findings of Turton et al. in several
important ways. First, when food intake is assessed over
longer intervals following bolus injections, the effect of
GLP-1 on food intake is found to be short-lived and
essentially non-existent after 24 h. Second, comparably to
what is seen in Long–Evans rats, IVT administration of
GLP-1 to fatty Zucker rats reduces 2 h but not 24 h food
intake. Hence, GLP-1 has a short functional time constant,
and the lack of a longer effect could be due to its short
half-life andror to compensation by other factors later in
the day. Finally, GLP-1 is comparably effective in fatty
Zucker rats as it is in lean Long Evans rats. All of these
actions fit a profile of a short-acting, meal-related satiety
factor.
To assess whether GLP-1 would be more efficacious if
given over a longer interval, we administered GLP-1 as a
continuous infusion into the third ventricle via osmotic
mini-pumps. Despite using a daily dose that is 10 times the
effective bolus dose, continuous infusion of GLP-1 had no
effect on food intake or body weight in either Long–Evans
or fatty Zucker rats. While there are always caveats associ-
ated with interpreting negative data especially when the
control conditions appear to have effects on food intake
and body weight, these data suggest that providing contin-
uous stimulation of central GLP-1 receptors does not
produce changes in daily food intake or body weight. The
results of Experiment 3 further suggest that the GLP-1
remained potent throughout the infusion interval, such that
the animals evidently became refractory to its anorexic
actions.
In the final experiment, animals were restricted to two 2
h intervals of feeding each day, a schedule on which they
were able to maintain their free-feeding body weights.
GLP-1 could thus be administered immediately prior to
each feeding bout, with the food being available for a
duration over which IVT administration of GLP-1 effec-
 .tively reduces intake cf. Fig. 1 . And whereas GLP-1 did
reliably reduce intake early in the paradigm, its anorexic
effect was reduced by the second day of treatment and
completely gone by the third day. Importantly, at no point
did GLP-1 reduce body weight, suggesting that infused
animals might have had reduced energy expenditure during
the periods when food intake is being reduced. Again,
caveats apply to such negative data. The control conditions
in this experiment repeated i3vt vehicle administration in
.animals with only 4 h access to food per day appeared to
have an effect to reduce food intake. It is possible that this
effect of the control condition obscured a small effect of
GLP-1 to continue to reduce food intake and body weight.
Collectively, however, the present experiments provide no
evidence that central administration of GLP-1 can influ-
ence long-term food intake or body weight.
The results with GLP-1 therefore contrast with those of
other peptides hypothesized to be long-term regulators of
food intake and body weight via actions in the CNS. When
either the pancreatic hormone insulin or the adipocyte
hormone leptin are infused into the third ventricle in
multiple boluses or continuously via osmotic mini-pumps,
they produce dose-dependent reductions of daily caloric
w xand, if continued, loss of body weight as well 1,15 . In
further contrast to the effects of GLP-1, fatty Zucker rats
are resistant to the food and body weight suppressive
effects of both insulin and leptin infused into the third
w xventricle 9,15 .
Finally, the pattern of neuronal activation as assessed
by c-fos immunohistochemistry is different for GLP-1 and
leptin. Leptin produces significant increases in c-fos-like-
 .immunohistochemistry c-FLI in several hypothalamic nu-
clei and in the central nucleus of the amygdala. In addition
to activation in these same brain regions, a dose of GLP-1
that produces similar reductions short-term food intake
also produces increased in c-FLI in several brainstem
nuclei, including the area postrema, the parabrachial nu-
w xcleus and the NTS 20 . Finally, at doses that produce
significant reductions in food intake and body weight,
w xneither insulin nor leptin 1,18 produce conditioned taste
aversions. Doses of GLP-1 that reduce food intake, how-
ever, cause the formation of robust conditioned taste aver-
w xsions 18,21 . Thus, the available data on the effects of
central administration of GLP-1 on food intake and body
weight do not support the hypothesis that GLP-1 has a role
in the regulation of long-term food intake and body weight.
The actions of GLP-1 in the CNS are seemingly more
analogous to those of CCK. Exogenous administration of
 .  .GLP-1 IVT or CCK i.p. or IVT reduces short-term food
intake in both lean and farfa Zucker rats without chang-
w xing daily caloric intake or body weight 12 . CCK receptor
antagonists, when administered alone, produce reliable
w xincreases of meal size 16 , and Turton et al. have evidence
w xthat this is also true for a GLP-1 antagonist 19 . GLP-1
and CCK also produce overlapping patterns of neuronal
w xactivation in the brainstem as measured by c-FLI 11,20 .
( )J.C.K. Donahey et al.rBrain Research 779 1998 75–83 83
Thus, if GLP-1 in the CNS does have a role as a homeo-
static regulator of food intake, it would appear to be as a
short-term satiety signal and not a long-term regulator of
caloric intake and body weight. On the other hand, unlike
GLP-1, CCK reduces meal size at doses that do not cause
conditioned taste aversions; and CCK does not cause a
generalized depression as has recently been reported for
w xGLP-1 6 . Hence, GLP-1 may act in a different manner to
effect food intake than satiety agents such as CCK.
The growing prevalence of obesity has produced a
 .pressing need and a lucrative market for pharmacological
treatments that could produce reductions in food intake
leading to reductions in body adiposity. The initial obser-
vation that GLP-1 administered into the third ventricle
produced a potent reduction of food intake made central
GLP-1 receptors attractive targets for developing phar-
macological interventions. However, an agonist for the
GLP-1 receptor administered into the CNS produces aver-
sive side effects as indicated by its ability to support
w x.robust conditioned taste aversions 18,21 . Further, the
present data support the hypothesis that producing reduc-
tions of long-term food intake and body weight with a
GLP-1 agonist is unlikely.
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